Name

Menarini Group

Legal name

A. Menarini Industrie Farmaceutiche Riunite S.r.l.

Website

https://menarini.com

Company type

Private

Founded year

1886

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Prescription pharmaceuticals
• Oncology therapeutics
• Consumer healthcare
• Clinical diagnostics
• Biopharmaceutical manufacturing

Headquarters

HQ city

Firenze

HQ country

Italy

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products: Revenue from prescription pharmaceutical products across multiple therapeutic areas including oncology, cardiometabolic, anti-infectives, respiratory, gastrointestinal, pain, and dermatology
2. Licensing and Royalties: Revenue from licensing agreements including selinexor (global rights outside US), obicetrapib (European rights), and AI-discovered drug candidates
3. Diagnostics: Revenue from professional diagnostics and advanced diagnostics including prenatal testing and rare cell analysis

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Menarini Group is a fully integrated privately owned pharmaceutical company that develops, manufactures, and commercializes prescription medicines, consumer healthcare (OTC) products, oncology therapeutics, diagnostics, and dermatology/aesthetic medicine products across more than 130 countries. Its core revenue drivers are prescription pharmaceuticals spanning anti-infectives, cardiometabolic, respiratory, gastrointestinal, pain, men's health, plus a growing oncology franchise centered on elacestrant (ORSERDU®), tagraxofusp, and the licensed products selinexor and obicetrapib. The company also sells professional and advanced diagnostics and prenatal testing through its diagnostics business, and OTC products through its consumer healthcare division.

Product overview

Menarini Group is a fully integrated privately owned pharmaceutical company operating across five core business areas: Pharmaceuticals (prescription medicines in anti-infectives, cardiometabolic, respiratory, gastrointestinal, pain, and men's health), Consumer Healthcare (OTC products including analgesics, cough/cold/allergy, and supplements), Oncology (including Stemline Therapeutics subsidiary with treatments for breast cancer, hematologic malignancies, and solid tumors), Diagnostics (professional, advanced, and prenatal testing), and Dermatology/Aesthetic Medicine (Relife brand). Key products include ORSERDU® (elacestrant) for ER+/HER2- metastatic breast cancer, Tagraxofusp for BPDCN, licensed products obicetrapib for cholesterol and selinexor for myelofibrosis, and pipeline assets including AI-discovered MEN2501. The company reported approximately €4.9 billion in 2025 revenue with 6.2% growth, investing in oncology and AI-enabled drug discovery through partnerships with Insilico Medicine and others.

Differentiator

Problem solved

Functional benefit

Brands

• ORSERDU: Brand name for elacestrant, an oral endocrine therapy for ER+/HER2- metastatic breast cancer
• Stemline Therapeutics
• Relife
• Fair Play Menarini
• Fondazione Menarini

Products and services

• Elacestrant (ORSERDU®) Oral selective estrogen receptor degrader (SERD) for the treatment of ER+/HER2- metastatic breast cancer, positioned as a backbone endocrine therapy for combination treatment. Marketed as ORSERDU®.
• Tagraxofusp CD123-targeted therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and hematologic malignancies, commercialized through Menarini's wholly-owned subsidiary Stemline Therapeutics.
• Selinexor (XPOVIO®) Selective inhibitor of nuclear export (SINE) compound (XPO1 inhibitor). Menarini holds global licensing rights outside the U.S. for myelofibrosis and other indications, including combination therapy with ruxolitinib.
• Obicetrapib CETP inhibitor for lowering LDL-C in patients with hypercholesterolemia. European commercialization rights exclusively licensed to Menarini Group from NewAmsterdam Pharma.
• MEN2501 Differentiated small molecule KIF18A inhibitor for chromosomally unstable solid tumors, AI-designed using Insilico Medicine's generative AI engine and licensed to Stemline Therapeutics. Currently in Phase 1 clinical trials.
• Consumer Healthcare Portfolio Over-the-counter (OTC) consumer healthcare products including analgesics, cough/cold/allergy remedies, gastrointestinals, lifestyle OTCs, and vitamins/minerals/supplements sold to retail and consumer markets.
• Diagnostics Portfolio Professional diagnostics for clinical settings, advanced diagnostics including rare cell analysis for personalized medicine, and prenatal testing services sold to healthcare institutions and laboratories.
• Relife Dermatology and Aesthetic Medicine Dermatology and aesthetic medicine brand under Menarini, focused on skin health and aesthetic treatments (tagline: 'My skin says how I feel').

Quantifiable outcome

• 49.8% spleen volume reduction (SVR35) at week 24 with selinexor-ruxolitinib combination vs 28% for ruxolitinib monotherapy in myelofibrosis patients
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Insilico MedicinecoreStrategic or Co-development Partner · 1 July 2025AI-driven drug discovery collaboration where Insilico Medicine designed MEN2501 (KIF18A inhibitor) using its generative AI engine. Menarini's subsidiary Stemline Therapeutics holds the license. The combined value of agreements exceeds USD 550 million, including milestone payments of USD 3 million (July 2025 after IND approval) and USD 5 million (after first-in-human dosing).
• ERBCminorStrategic or Co-development Partner · 3 April 2025Strategic partnership to help biopharmaceutical companies transition from research stage to First-In-Human clinical trials, combining preclinical expertise with CMC capabilities for integrated services including non-clinical studies, regulatory-ready data modules, and scalable manufacturing.
• Karyopharm TherapeuticscoreStrategic or Co-development PartnerCollaboration on selinexor for myelofibrosis treatment. Menarini Group holds global licensing rights for selinexor outside the United States. The Phase 3 SENTRY trial was conducted by Karyopharm and results were presented at EHA 2026 congress, showing statistically significant spleen volume reduction improvement with the selinexor-ruxolitinib combination.
• NewAmsterdam PharmacoreOEM/ Whitelabel/ Licensing PartnerMenarini Group holds exclusive commercialization rights for obicetrapib (CETP inhibitor) in Europe. NewAmsterdam is developing the drug for hypercholesterolaemia with EMA expected to issue regulatory decision in H2 2026.
• Stemline TherapeuticscoreOthersWholly-owned subsidiary of Menarini Group focused on bringing transformational oncology treatments to cancer patients. Based in the United States, Stemline commercializes elacestrant (ORSERDU®) and tagraxofusp, and holds licenses for selinexor and MEN2501.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Bayer AG: German-headquartered diversified life sciences group with pharmaceuticals, consumer health, and crop science. Comparable to Menarini in European roots, diversified therapeutic portfolio, and consumer healthcare scale.
• Roche Holding AG: Swiss-headquartered global pharmaceutical leader with the largest oncology franchise in the industry, complemented by diagnostics. Comparable on oncology pipeline depth and diagnostics business overlap.
• Merck KGaA: German diversified science and technology company with healthcare, life science, and electronics. Comparable European mid-large pharma with oncology, neurology, and fertility therapeutic areas.
• GSK plc: UK global biopharma with pharmaceuticals, vaccines, and consumer healthcare. Comparable to Menarini on consumer healthcare (OTC), respiratory, and oncology overlap.
• Teva Pharmaceutical Industries Ltd. Israel-headquartered global pharmaceutical company with large specialty and generics franchise. Comparable on broad geographic commercial reach and diversified therapeutic portfolio.
• AstraZeneca PLC: UK-headquartered global biopharmaceutical company with leadership in oncology, cardiometabolic, and respiratory. Comparable on the same oncology and cardiometabolic therapeutic areas that anchor Menarini's recent launches.
• Sanofi: French global pharmaceutical company with strong European presence, consumer healthcare (OTC), specialty care, and oncology pipeline. Comparable diversified European pharma with comparable revenue scale and therapeutic breadth.

Direct peers

• Almirall S.A. Spanish privately-listed mid-pharma focused on dermatology and specialty care. Comparable European specialty pharma with overlapping consumer health and derma/aesthetic medicine profile.
• Chiesi Farmaceutici S.p.A. Italian privately-owned pharmaceutical group operating in respiratory, neonatology, and rare diseases. Comparable privately-held European mid-pharma with focus on specialty therapeutic areas.
• Recordati S.p.A. Italian-headquartered mid-cap specialty pharmaceutical company with focus on cardiovascular, urology, and rare diseases. Closely comparable to Menarini in European, family-influenced pharma operating model and therapeutic focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/MenariniGroup
• LinkedInlinkedin.com/company/menarini

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Menarini Group